Grace Therapeutics (GRCE) Receivables - Net (2017 - 2024)

Grace Therapeutics has disclosed Receivables - Net across 8 years of filings, most recently posting $398000.0 for Q2 2024.

• In Q2 2024, Receivables - Net fell 52.45% year-over-year to $398000.0; the TTM figure through Jun 2024 stood at $398000.0 (down 52.45% YoY), while the FY2024 annual figure was $722000.0, down 9.98% from the prior year.
• Receivables - Net came in at $398000.0 for Q2 2024 at Grace Therapeutics, down from $722000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $964000.0 in Q2 2022 to a low of $238000.0 in Q4 2021.
• Average Receivables - Net over 5 years is $667666.7, with a median of $673500.0 recorded in 2020.
• Year-over-year, Receivables - Net sank 61.55% in 2021 and jumped 226.89% in 2022.
• Over 5 years, Receivables - Net stood at $619000.0 in 2020, then slumped by 61.55% to $238000.0 in 2021, then jumped by 226.89% to $778000.0 in 2022, then increased by 23.26% to $959000.0 in 2023, then sank by 58.5% to $398000.0 in 2024.
• Per Business Quant data, the three most recent Receivables - Net figures were $398000.0 in Q2 2024, $722000.0 in Q1 2024, and $959000.0 in Q4 2023.